To evaluate the long-term safety through 15 years post infusion of patients who received IP in a Caribou-sponsored study, special access program or ITT
This study is a long-term follow-up study of cell therapy in patients who received IP in a parent study: a Caribou-sponsored clinical trial, through a special access program, or an ITT. Patients must provide informed consent to the LTFS and meet study eligibility requirements to participate.
Completed a Caribou-sponsored study or was administered Caribou IP under a special accessprogram or as part of an IIT. Written informed consent (by patient or legal representative) obtained prior to study-specificactivities/enrollment. 2.Completed a Caribou-sponsored study or was administered Caribou IP under a special accessprogram or as part of an IIT. Long-Term Follow-up Study Version 3.0 CONFIDENTIAL AND PROPRIETARY Page 15 of 46 3. Use of an effective method of birth control by women of childbearing potential and their partners and men with partners of childbearing potential (partners
Protocol Number: 24-0659
More information available at ClinicalTrials.gov: NCT05332054
Principal Investigator